文献速递呼吸危重症与机械通气

改善急性呼吸窘迫综合征临床试验设计的机遇

Opportunities for improved clinical trial designs in acute respiratory distress syndrome.
PubMed 文献 · Lancet Respir Med · 2022-01-01

急性呼吸窘迫综合征(ARDS)是常见危重症,病死率高且尚无已证实的药物治疗。本文指出当前ARDS定义基于共同临床特征,未涵盖临床危险因素、影像、生理、起病时间与轨迹及生物学的异质性。作者建议通过开发靶向可治疗特征的新方法和提高试验代表性(纳入全球人群)来改进未来ARDS试验设计,并讨论了ARDS定义扩展对试验的影响。

要点

  • ARDS尚无已证实的药物治疗,试验设计需减少人群异质性。
  • 推荐开发靶向可治疗特征的方法并提高全球代表性。
  • ARDS定义扩展可能影响未来临床试验设计。

核心结论

  • 改善ARDS临床试验需平衡减少人群异质性与制定包容性全球定义,两种策略互补共存。

研究设计与样本

  • 本文为Personal View,未报告系统检索范围或样本量。

主要发现

  • 当前ARDS定义基于共同临床特征,未捕捉临床危险因素、影像、生理、起病时间与轨迹及生物学的异质性。

关键数值与推荐

  • 推荐两种主要策略:开发靶向临床试验人群中可治疗特征的新方法,以及提高ARDS试验代表性并纳入全球人群。

临床怎么用

  • 未来ARDS试验设计可考虑靶向可治疗特征并纳入全球多样化人群以提高代表性。

局限性

  • 本文为观点性文章,未报告原始研究数据或系统评价结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The acute respiratory distress syndrome (ARDS) is a common critical illness syndrome with high morbidity and mortality. There are no proven pharmacological therapies for ARDS. The current definition of ARDS is based on shared clinical characteristics but does not capture the heterogeneity in clinical risk factors, imaging characteristics, physiology, timing of onset and trajectory, and biology of the syndrome. There is increasing interest within the ARDS clinical trialist community to design clinical trials that reduce heterogeneity in the trial population. This effort must be balanced with ongoing work to craft an inclusive, global definition of ARDS, with important implications for trial design. Ultimately, the two aims-to design trials that are applicable to the diverse global ARDS population while also advancing opportunities to identify targetable traits-should coexist. In this Personal View, we recommend two primary strategies to improve future ARDS trials: the development of new methods to target treatable traits in clinical trial populations, and improvements in the representativeness of ARDS trials, with the inclusion of global populations. We emphasise that these two strategies are complementary. We also discuss how a proposed expansion of the definition of ARDS could affect the future of clinical trials.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Wick KD, Aggarwal NR, Curley MAQ, et al. Opportunities for improved clinical trial designs in acute respiratory distress syndrome. Lancet Respir Med. 2022. PMID: 36057279. doi:10.1016/S2213-2600(22)00294-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。